|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-5-1
|
|
pubmed:abstractText |
This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
67-72
|
|
pubmed:meshHeading |
pubmed-meshheading:18936940-Adult,
pubmed-meshheading:18936940-Aged,
pubmed-meshheading:18936940-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18936940-Camptothecin,
pubmed-meshheading:18936940-Cohort Studies,
pubmed-meshheading:18936940-Colorectal Neoplasms,
pubmed-meshheading:18936940-Deoxycytidine,
pubmed-meshheading:18936940-Dose-Response Relationship, Drug,
pubmed-meshheading:18936940-Drug Eruptions,
pubmed-meshheading:18936940-Female,
pubmed-meshheading:18936940-Fever,
pubmed-meshheading:18936940-Fluorouracil,
pubmed-meshheading:18936940-Humans,
pubmed-meshheading:18936940-Male,
pubmed-meshheading:18936940-Maximum Tolerated Dose,
pubmed-meshheading:18936940-Middle Aged,
pubmed-meshheading:18936940-Mucositis,
pubmed-meshheading:18936940-Neoplasm Metastasis,
pubmed-meshheading:18936940-Neutropenia,
pubmed-meshheading:18936940-Quinazolines
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
|
|
pubmed:affiliation |
Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. emilio.bajetta@istitutotumori.mi.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
